mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation
Theyve shown amazing potential for diagnosis and treatment
Patel V, Menezes H, Menezes C, Bouwer S, Bostick-Smith CA, Speelman DL
c bit l ph n mun duy tr nt thanh xun ti tr , da d mn mng , cng bng , khng b nm, sm, nhn nheo
Evidence-Based Improvements in Clinical Practice Enhanced Clinical Assessment Protocols Structured clinical assessment protocols can substantially improve diagnostic accuracy while reducing provider variability
Butyrate production from dietary fibre and protection against large bowel cancer in a rat model
